Previous 10 | Next 10 |
2024-01-02 12:56:48 ET More on Mid-day movers & stocks. ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Endra Life Sciences Historical earnings da...
2024-01-02 10:00:09 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...
2023-12-29 13:02:59 ET Gainers: Sentage Holdings ( SNTG ) +262% . China SXT Pharmaceuticals ( SXTC ) +107% . China Green Agriculture ( CGA ) +54% . Aditxt ( ADTX ) +33% . TC BioPharm ( TCBP ) +30% . Bright Health Group ( BH...
2023-12-28 10:00:05 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, and R1 RCM are Citi’s top stocks in healthcare For further details see:...
This study will be the Second Clinical Trial Evaluating RenovoGem™, a Combination Drug-Device Product, in a Difficult-to-Access Solid Tumor Cancer RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical compan...
Research Supports RenovoRx’s Lead Oncology Product Candidate, RenovoGem™, and its Novel Therapy Platform, TAMP™, for the Treatment of Locally Advanced Pancreatic Cancer RenovoRx, Inc . (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel p...
RenovoRx Holds a Strong Intellectual Property (IP) Portfolio with 9 Issued Patents for its Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Therapy Platform and Delivery System New Patent Would Expand IP Coverage for TAMP to Deliver Additional Therapeutic Classes Across DNA/RNA A...
RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board (S...
2023-11-14 10:22:24 ET More on RenovoRx Seeking Alpha’s Quant Rating on RenovoRx Historical earnings data for RenovoRx Financial information for RenovoRx For further details see: RenovoRx GAAP EPS of -$0.13
Collaboration with Imugene further validates TAMP TM (Trans-Arterial Micro-Perfusion) and will expand use of RenovoRx’s delivery platform beyond chemotherapy to immunotherapy. The TAMP therapy platform is in a Phase III clinical trial for the treatment of Pancreatic Cancer, int...
News, Short Squeeze, Breakout and More Instantly...
LOS ALTOS, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today annou...
LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...